• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Zoledronate Disodium Tetrahydrate

Zoledronate Disodium Tetrahydrate

Product ID Z5645
Cas No. 165800-07-7
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $78.10 In stock
10 mg $128.60 In stock
25 mg $236.40 In stock
100 mg $661.80 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Zoledronate is a sodium salt form of zoledronic acid. Zoledronic acid is a third generation bisphosphonate that exhibits anti-resorptive, anti-osteoporotic, anti-angiogenic, and anticancer chemotherapeutic activities. In giant cell tumor bone stromal cells, zoledronic acid increases expression of Cbfa-1, osteocalcin, and osterix, inducing apoptosis and osteogenic differentiation; it also inhibits bone resorption and prevents osteoporosis in animal models. In animal models of renal cell carcinoma, zoledronic acid decreases mean vessel density. In breast cancer cells, zoledronic acid reverses the epithelial-to-mesenchymal transition (EMT) by inactivating NF-κB, decreasing self-renewal and cell proliferation. In other cellular models, zoledronic acid inhibits farnesyl diphosphate synthase (FPPS), which results in activation of γδ T cells. Across several breast cancer cell lines, zoledronic acid activates caspases 3, 8, and 9 and decreases expression of Ras and MAPK, resulting in the induction of cell cycle arrest or apoptosis.

Product Info

Cas No.

165800-07-7

Purity

≥98%

Formula

C5H10N2O7P2 • 2Na • 4H2O

Formula Wt.

390.13

Chemical Name

[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]- bisphosphonic acid disodium salt tetrahydrate

IUPAC Name

disodium;(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid;tetrahydrate

Synonym

Zoledronic acid disodium salt tetrahydrate

Melting Point

305-307°C

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

Z5645 MSDS PDF

Info Sheet

Z5645 Info Sheet PDF

References

Yang T, Zheng XF, Li M, et al. Stimulation of osteogenic differentiation in stromal cells of giant cell tumour of bone by zoledronic acid. Asian Pac J Cancer Prev. 2013;14(9):5379-83. PMID: 24175830.

Schech AJ, Kazi AA, Gilani RA, et al. Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB. Mol Cancer Ther. 2013 Jul;12(7):1356-66. PMID: 23619300.

Idrees AS, Sugie T, Inoue C, et al. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. Cancer Sci. 2013 May;104(5):536-42. PMID: 23387443.

Ibrahim T, Mercatali L, Sacanna E, et al. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int. 2012 Nov 22;12(1):48. PMID: 23173568.

Soltau J, Zirrgiebel U, Esser N, et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res. 2008 Mar-Apr;28(2A):933-41. PMID: 18507039.

Kavanagh KL, Guo K, Dunford JE, et al The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-34. PMID: 16684881.

Takahashi H, Kinbara M, Sato N, et al. Nickel allergy-promoting effects of microbial or inflammatory substances at the sensitization step in mice. Int Immunopharmacol. 2011 Oct;11(10):1534-1540. PMID: 21621645.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • L5769

    Lorglumide Sodium

    CCK antagonist.

    ≥98%
  • E8401

    Evacetrapib

    Cholesterol ester transfer protein inhibitor.

    ≥98%
  • A9708

    AZD-1208

    Pim-1 inhibitor.

    ≥98%
  • T6903

    Tranylcypromine Hydrochloride

    MAO and histone demethylase LSD1 inhibitor.

    ≥98%
  • K0021

    K252a

    Staurosporine analog; PKC inhibitor, TrkA/B ant...

    ≥98%
  • C0278

    (+)-Catechin

    Flavanol originally found in Camilla (green tea...

    ≥99%
  • T1754

    Tenatoprazole

    H+/K+ ATPase inhibitor.

    ≥98%
  • V3252

    Vinorelbine Ditartrate

    Semi-synthetic vinca alkaloid from Catharanthus...

    ≥98%
  • T1672

    Terbinafine Hydrochloride

    Allylamine; squalene oxidase and KSR1 inhibitor...

    ≥98%
  • M8007

    Mubritinib, Free Base

    EGFR2 inhibitor.

    ≥99%
  • H9763

    Hypoxanthine

    Endogenous purine derivative of xanthine.

    ≥98%
  • N3584

    Nivalenol

    Trichothecene mycotoxin produced by Fusarium; p...

    ≥98%
  • A480000

    AM251

    CB1 receptor antagonist/ inverse agonist.

    ≥97%
  • H966144

    6-Hydroxydopamine Hydrobromide

    Neurotoxin frequently used to aid in modeling P...

    ≥98%
  • D0006

    Dacomitinib Monohydrate

    EGFR inhibitor.

    ≥99%
  • T6930

    Triclosan Methyl Ether

    Diarylether; bacterial ENR binder, fatty acid s...

    ≥99%
  • T1027

    2’-Benzoylcarbonyl D-seco-Taxol

    2’-Benzoylcarbonyl D-seco-Taxol is an impurit...

    ≥90%
  • A488246

    AMG-232

    MDM2-p53 inhibitor

    ≥99%
  • S3449

    Simvastatin

    Statin; HMG-CoA reductase inhibitor, potential ...

    ≥98%
  • G4532

    Gliclazide

    Sulfonylurea; SUR1 antagonist.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only